ICER reaf­firms Qsymia as most cost-ef­fec­tive obe­si­ty treat­ment in fi­nal re­port

Last Ju­ly, the cost-ef­fec­tive­ness drug watch­dog ICER re­leased a pre­lim­i­nary draft re­port that Vivus’ Qsymia was the most cost-ef­fec­tive op­tion for weight loss. That de­ci­sion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER